Patents by Inventor James R. Berenson

James R. Berenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS
    Publication number: 20230233579
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Application
    Filed: August 25, 2022
    Publication date: July 27, 2023
    Inventor: James R. BERENSON
  • Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
    Patent number: 11246876
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: February 15, 2022
    Assignee: OncoTracker, Inc.
    Inventor: James R. Berenson
  • ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS
    Publication number: 20200030343
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Application
    Filed: May 7, 2019
    Publication date: January 30, 2020
    Applicant: OncoTracker, Inc.
    Inventor: James R. BERENSON
  • Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids
    Patent number: 10363260
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 30, 2019
    Assignee: OncoTracker, Inc.
    Inventor: James R. Berenson
  • DIAGNOSTIC, PROGNOSTIC, AND MONITORING METHODS FOR MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, AND B-CELL NON-HODGKIN LYMPHOMA
    Publication number: 20190107541
    Abstract: The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.
    Type: Application
    Filed: September 28, 2018
    Publication date: April 11, 2019
    Applicant: INSTITUTE FOR MYELOMA & BONE CANCER RESEARCH
    Inventors: James R. BERENSON, Haiming CHEN, Eric SANCHEZ
  • Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
    Patent number: 10126301
    Abstract: The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: November 13, 2018
    Assignee: Institute for Myeloma & Bone Cancer Research
    Inventors: James R. Berenson, Haiming Chen, Eric Sanchez
  • ANTI-CANCER EFFECTS OF PROTEASOME INHIBITORS IN COMBINATION WITH GLUCOCORTICOIDS, ARSENIC CONTAINING COMPOUNDS, AND ASCORBIC ACID
    Publication number: 20170224730
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a proteasome inhibitor, a glucocorticoid, an arsenic-containing compound, and ascorbic acid or a derivative thereof provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or relapsed hematologic disorders.
    Type: Application
    Filed: June 10, 2015
    Publication date: August 10, 2017
    Applicant: Institute for Myeloma & Bone Cancer Research
    Inventor: James R. BERENSON
  • ANTI-CANCER EFFECTS OF JAK2 INHIBITORS IN COMBINATION WITH THALIDOMIDE DERIVATIVES AND GLUCOCORTICOIDS
    Publication number: 20170106003
    Abstract: The present invention provides methods of treatment for hematological malignancies involving synergistic combination of a JAK2 inhibitor and a glucocorticoid or a JAK2 inhibitor, thalidomide or thalidomide derivative, and a glucocorticoid. The compositions and methods provide an unexpected efficacy in the treatment for hematological disorders. The hematological disorders treated by the current invention include multiple myeloma, and may also include hematological disorders that are refractory to prior cancer treatments, or a relapsed hematologic disorder.
    Type: Application
    Filed: May 28, 2015
    Publication date: April 20, 2017
    Applicant: Institute for Myeloma & Bone Cancer Research
    Inventor: James R. BERENSON
  • DIAGNOSTIC, PROGNOSTIC, AND MONITORING METHODS FOR MULTIPLE MYELOMA, CHRONIC LYMPHOCYTIC LEUKEMIA, AND B-CELL NON-HODGKIN LYMPHOMA
    Publication number: 20160131654
    Abstract: The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.
    Type: Application
    Filed: February 7, 2014
    Publication date: May 12, 2016
    Inventors: James R. BERENSON, Haiming CHEN, Eric SANCHEZ
  • Combination therapy for the treatment of multiple myeloma
    Patent number: 8765720
    Abstract: The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 1, 2014
    Assignee: Cephalon, Inc.
    Inventor: James R. Berenson
  • Combination Therapy for the Treatment of Multiple Myeloma
    Publication number: 20120071445
    Abstract: The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.
    Type: Application
    Filed: November 9, 2011
    Publication date: March 22, 2012
    Applicant: Cephalon, Inc.
    Inventor: James R. Berenson